Although, as previously described, several in vitro investigations observed that the migratory and metastatic potential of human tumor cells can significantly be reduced by a SEC62 siRNA transfection (Greiner et al., 2011a; Linxweiler et al., 2012, 2016; Bochen et al., 2017), transfer of this technology to humans does not appear possible at present. The gene discussed is SEC62; the disease is neoplasm.